<DOC>
	<DOCNO>NCT00582894</DOCNO>
	<brief_summary>To evaluate engraftment toxicity reduce intensity preparative regimen patient receive match related unrelated donor allogeneic stem cell transplant ( ASCT ) malignant hematological disease</brief_summary>
	<brief_title>Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Malignant Hematological Diseases</brief_title>
	<detailed_description>Primary Endpoints : 1 . Engraftment donor cell 2 . Regimen related toxicity Secondary Endpoints : 1 . Disease-free survival 2 . Overall survival</detailed_description>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Performance status 02 Ejection fraction &gt; 30 % AST/ALT bilirubin &gt; 4 time normal Creatinine clearance great 70 ml/min . FEV1 great 1.0 diffusion capacity great 40 % Age 1875 year Patients must high risk conventional regimen relate toxicity Malignant hematologic disease would otherwise consider treatable ASCT Does meet Inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Allogenic stem cell transplant</keyword>
	<keyword>Hematologic disease</keyword>
</DOC>